Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MC4R | P32245 | 11/20 | 0.45 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
| ▸ | APEX1 | P27695 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | BLM | P54132 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 2/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.40 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.40 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.40 |
| ▸ | MC5R | P33032 | 1/20 | 0.39 |
| ▸ | MC3R | P41968 | 1/20 | 0.39 |
| ▸ | MC1R | Q01726 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2344486 | 0.94 | MC4R (0.48) | MC4RMEN1KMT2ATP53TSHR | |
| SCHEMBL3408856 | 0.94 | MC4R (0.48) | MC4RMEN1KMT2ATP53TSHR | |
| SCHEMBL3014397 | 0.82 | MC4R (0.40) | MC4RMEN1KMT2AMAPTPOLB | |
| SCHEMBL3633209 | 0.80 | MEN1 (0.43) | PKMAPEX1CYP2C19BLMHSD17B10 | |
| SCHEMBL3636883 | 0.79 | MEN1 (0.51) | PKMAPEX1CYP2C19BLMHSD17B10 | |
| SCHEMBL442668 | 0.78 | MC4R (0.54) | MC4RCYP3A4 | |
| SCHEMBL17871701 | 0.78 | MC4R (0.54) | MC4RCYP3A4 | |
| SCHEMBL1964089 | 0.78 | MC4R (0.54) | MC4RCYP3A4 | |
| SCHEMBL31388217 | 0.78 | MC4R (0.54) | MC4RCYP3A4 | |
| SCHEMBL31128130 | 0.78 | MC4R (0.54) | MC4RCYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100197732-A1 | Repaglinide Substantially Free of Dimer Impurity | ACTAVIS GROUP PTC EHF (IS) | 2010-08-05 | — | — | US | disclosed |
| EP-2155706-A2 | REPAGLINIDE SUBSTANTIALLY FREE OF DIMER IMPURITY | Actavis Group PTC EHF (IS) | 2010-02-24 | — | — | EP | disclosed |
| WO-2009004485-A2 | REPAGLINIDE SUBSTANTIALLY FREE OF DIMER IMPURITY | ACTAVIS GROUP PTC EHF (IS) | 2009-01-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100197732-A1 | Repaglinide Substantially Free of Dimer Impurity | EMG1, DAP3, DRD4 | MC4R 1094/4885PKM 3315/4885APEX1 1616/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.